Acetazolamide |
60 days at 25 ºC and 40 ºC |
Santoveña et al., 2016bSantoveña A, Suarez-Gonzalez J, Martın-Rodrıguez C, Farina JB. Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study. Pharm Dev Technol. 2016b;22(2):191-197.
|
Alprazolam |
60 days at 25 ºC |
Allen, Erickson, 1998Allen LV, Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1998;55(18):1915-20.
|
Amlodipine |
1 year at 4 ºC in absence of light |
Vossen et al., 2016Vossen AC, Velde I, Meiracker AH, Nagel BCH, Koch BCP, Vulto AG, et al. Bioequivalence study of a newly developed oral solution of amlodipine and commercial tablets after single-dose administration in healthy volunteers. Int J Clin Pharmacol Ther. 2016;54(1):65-72.
|
Aripiprazole |
91 days at 4 ºC |
Pramann et al., 2016Pramann LA, Davidow LW, Haandel L, Funk RS. Development of extemporaneously compounded Aripiprazole oral suspensions for use in children. Int J Pharm Compd. 2016;20(3):257-261.
|
Atorvastatin |
30 days at 8 ºC or 25 ºC |
Zaid et al., 2016Zaid AN, Assali M, Zalmout S, Bashee A. Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder. Eur J Hosp Pharm. 2016;1-5.
|
Bosentan |
31 days at 21-26 ºC |
Malik et al., 2016Malik A, Gorman G, Coward L, Arnold JJ. Stability of an extemporaneously compounded oral suspension of bosentan. HospPharm. 2016;51(5):389-395.
|
Capecitabina |
14 days at 8 ºC in absence of light |
Romero et al., 2016Romero RM, Corpas MV, Medina MDCG, Peña CG, Romero AC, Guardia AVR, et al. Extemporaneous preparation of oral liquid formulation of capecitabina. Eur J Hosp Pharm. 2016;23(S1):A1-262.
|
Captopril |
45 days at 5 ºC |
Dysarz, 2017Dysarz LP. Desenvolvimento e caracterização de uma formulação magistral líquida de captopril 0,5%. [Master´s Dissertation]. Rio de Janeiro: Faculdade de Farmácia, UFRJ; 2017.
|
Carbidopa |
30 days at 20-25 ºC and 90 days at 2-8 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Carvedilol |
8 weeks at 22-26 ºC or 4-8ºC |
Yamreudeewon, Dolence, Pahl, 2006Yamreudeewong W, Dolence KE, Pahl D. Stability of two extemporaneously prepared oral metoprolol and carvedilol liquids. Hospital Pharm. 2006;41(3):254-259.
|
Celecoxib |
90 days at 40 ºC |
Kiel et al., 2016Kiel JS, Bryant TJ, Le Vasseur RG, Thomas HG. Liquid formulations of celecoxib for oral administration. Patent No. 20160346300. US; A1, 2016.
|
Chloroquine |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Chlorpromazine |
90 days at 2-8 ºC or 22-25 ºC |
Prohotsky, Juba, Zhao, 2014Prohotsky DL, Juba KM, Zhao F. Formulation and stability of an extemporaneously compounded oral solution of chlorpromazine HCl. J Pain Palliat Care Pharmacother. 2014;28(4):367-70.
|
Cinacalcet |
64 days at 2-8 ºC or 22-25 ºC in absence of light |
Thomson, Hutchinson, Chablani, 2018Thomson K, Hutchinson DJ, Chablani L. Stability of extemporaneously prepared cinacalcet oral suspensions. Am J Health-Syst Pharm. 2018;75(9):e236-e240.
|
Cholecalciferol |
90 days at 2-8 ºC or 20-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Clobazam |
56 days at 4 ºC or 25 ºC |
Buontempoa et al.,2013Buontempoa F, Morettona MA, Quirogad E, Chiappetta DA. Extemporaneous clobazam suspensions for pediatric use prepared from commercially available tablets and pure drug. Farm. Hospit. 2013;37(2):103-110.
|
Clomipramine |
90 days at 5 ºC or 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Clonazepam |
60 days at 5 ºC or 25 ºC |
Allen, Erickson, 1996bAllen LV, Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996b;53(16):1944-49.
|
Clonidine |
91 days at 4 ºC or 25 ºC |
Ma, Decarie, Ensom, 2014;Ma C, Decarie D, Ensom MHH. Stability of clonidine suspension in oral plastic syringes. Am J Health-Syst Pharm. 2014;71(15):657-61.
Ensom, Decarie, 2014Ensom MHH, Decarie D. Stability of extemporaneously compounded Clonidine in glass and plastic bottles and plastic syringes. Can J Hosp Pharm . 2014;67(4):308-310.
|
Dapsone |
91 days at 4 ºC or 25 ºC |
Nahata, Morosco, Trowbridge, 2000Nahata MC, Morosco RS, Trowbridge JM. Stability of dapsone in two oral liquid dosage forms. Ann Pharmacother. 2000;34(7/8):848-850.
|
Diazoxide |
90 days 5 ºC or 25 ºC in absence of light |
Friciu et al., 2016bFriciu M, Zaraa S, Roullin VG, Leclair G. Stability of diazoxide in extemporaneously compounded oral suspensions. PLoS One. 2016b;11(10):1-12.
|
Diltiazem |
60 days at 5 ºC or 25 ºC |
Allen, Erickson, 1996aAllen LV, Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996a;53(18):2179-84.
|
Enalapril |
30 days at 25 ºC in absence of light |
Sosnowska, 2009Sosnowska K. Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets. Acta Pol Pharmaceut - Drug Res. 2009;66(3):321-326.
|
Erlotinib |
28 days at 25 ºC in absence of light |
Li et al., 2016Ma C, Decarie D, Ensom MHH. Stability of clonidine suspension in oral plastic syringes. Am J Health-Syst Pharm. 2014;71(15):657-61.
|
Flecainide |
30 days at 25 ºC in absence of light |
Santoveña et al., 2016aSantoveña A, Charola I, Suárez-González J, Teigell-Pérez N, García-van Nood S, Soriano M. Development of a novel physico-chemically and microbiologically stable oral solution of flecainide for pediatrics. Pharm Dev Technol. 2016a;23:1-29.
|
Folicacid |
90 days at 5 ºC and 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Furosemide |
270 days at 25 ºC at 40 ºC |
Zahálka et al., 2017Zahálka L, Klovrzová S, Matysová L, Šklubalová Z, Solich P. Furosemide ethanol-free oral solutions for paediatric use: formulation, HPLC method and stability study. Eur J Hosp Pharm. 2017;1-6.
|
Gabapentin |
90 days at 25 ºC |
Friciu, Roullin, Leclair, 2017Friciu M, Roullin VG, Leclair G. Stability of gabapentin in extemporaneously compounded oral suspensions. PLoS One. 2017;12(4):1-11.
|
Glibenclamide |
90 days at 4 ºC, 25 ºC or 40 ºC |
Estevez et al., 2016Estevez P, Boscolo O, Quiroga E, Penuto RF, Buontempo F, Tripodi V, et al. Development and stability study of glibenclamide oral liquid paediatric formulations for the treatment of permanent neonatal diabetes mellitus. Eur J HospPharm. 2016;23(4):213-218.
|
Haloperidol |
90 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Hydrochlorothiazide |
90 days at 5 ºC or 25 ºC |
Poloniniet al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Idebenone |
90 days at 5 ºC or 25 ºC in absence of light |
Schlatter et al, 2017Schlatter J, Bourguignon E, Majoul E, Kabiche S, Balde I-B, Cisternino S. Stability study of oral pediatric idebenone suspensions. J Pharm Dev Tech. 2017;22(2):296-9.
|
Imatinib |
14 days at 5 ºC or 25 ºC in light or absence of light |
Li et al., 2016Li Q, Liu Z, Shamalatha K, Karen W, Niesha G, Poi MJ. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions. Am J Health-System Pharm. 2016;73(17):1331-7.
|
Imipramine |
90 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Isotretinoin |
6 months at 40-42 ºC |
Montwani, Isloor, Arora, 2015Motwani SK, Isloor SP, Arora VK .Liquid dosage forms of isotretinoin. Patent No. 20170165217. US; A1, 2017.
|
Lapatinib |
28 days at 25 ºC |
Li et al., 2016Li Q, Liu Z, Shamalatha K, Karen W, Niesha G, Poi MJ. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions. Am J Health-System Pharm. 2016;73(17):1331-7.
|
Levodopa |
30 days at 20-25 ºC and 90 days at 2-8 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Levofloxacin |
57 days at 23-25 ºC |
Vanden Bussche et al., 1999Vanden Bussche HL, Johnson CE, Fontana EM, Meram JM. Stability of levofloxacin in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1999;56(22):2316-2318.
|
Lisinopril |
4 weeks at ≤ 25 ºC |
Thompson et al., 2003Thompson KC, Zhao Z, Mazakas JM, Beasley CA, Reed RA, Moser CL. Characterization of an extemporaneous liquid formulation of lisinopril. Am J Health Syst Pharm. 2003;60(1):69-74.
|
Loperamide |
90 days at 5 ºC or 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Lorazepam |
60 days at 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Melatonin |
90 days at 3-5 ºC and 23-27 ºC |
Friciu et al., 2016aFriciu M, Savji T, Zara S, Leclair G. Evaluation of stability of melatonin in extemporaneously compounded oral suspensions. J Pharm Practice Res. 2016a;46(1):28-33.
|
Metformin |
30 days at 4-40 ºC in the presence or absence of light |
Alemon-Medina et al., 2014Alemon-Medina R, Chavez-Pacheco JL, Ramires-Mendiola B, Riviera-Espinosa L, Garcia-Alvares. Physicochemical stability of three generic brands of metformin in solution. Acta Ped México. 2014;35(2):94-99.
|
Methadone |
90 days at 4 ºC and 25 ºC |
Provenza et al., 2016Provenza N, Calpena AC, Mallandrich M, Pueyo M, Clares B. Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. Pharm Dev Technol. 2016;21(6):775-62.
|
Methotrexate |
90 days at 5 ºC or 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Metoprolol |
8 weeks at 22-26 ºC or 4-8ºC |
Yamreudeewong, Dolence, Pahl, 2006Yamreudeewong W, Dolence KE, Pahl D. Stability of two extemporaneously prepared oral metoprolol and carvedilol liquids. Hospital Pharm. 2006;41(3):254-259.
|
Minocycline |
10 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Minoxidil |
10 weeks at 2-4 ºC in absence of light |
Song et al., 2018Song Y, Chin ZW, Ellis D, Lwin EMP, Turner S, Williams D, Garg S. Stability of an extemporaneously compounded minoxidil oral suspension. Am J Health-Syst Pharm. 2018;75(5):309-315.
|
Moxifloxacin |
90 days at 23-25 ºC |
Hutchinson, Johnson, Klein, 2009Hutchinson DJ, Johnson CE, Klein KC. Stability of extemporaneously prepared moxifloxacin oral suspensions. Am J Health-Syst Pharm. 2009;66(7):665-7.
|
Nadolol |
90 days at 5 ºC or 25 ºC |
Polonini et al. 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Naltrexone |
90 days at 5 ºC or 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Naproxen |
91 days at 4 ºC and 25 ºC |
Ensom, Decarie, Lingertat-Walsh, 2015Ensom MHH, Decarie D, Lingertat-Walsh K. Stability of extemporaneously compounded Naproxen 25 mg/mL suspension in glass and plastic bottles and plastic Syringes. Can J HospPharm. 2015;68(6):489-491.
|
Norfloxacin |
56 days at 23-25 ºC |
Johnson, Price, Hession, 2001Johnson CE, Price J, Hession JM. Stability of norfloxacin in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 2001;58(7):577-579.
|
Oseltamivir |
35 days at 5 ºC or 25 ºC or 13 days at 30 ºC |
Winiarski et al., 2007Winiarski AP, Infeld MH, Tscherne R, Bachynsky M, Rucki R, Nagano-Mate K. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc. 2007;47(6):747-755.
|
Pentoxifylline |
90 days at 5 ºC or 25 ºC |
Polonini et al., 2016aPolonini HC, Silva SL, Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 2016a;23(6):352-358.
|
Phenobarbital |
60 days at 4 ºC and 30 days at 25 ºC |
Provenza et al., 2016Provenza N, Calpena AC, Mallandrich M, Pueyo M, Clares B. Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. Pharm Dev Technol. 2016;21(6):775-62.
|
Phenytoin |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Propafenone |
90 days at 3-5 ºC or 15±5 ºC |
Olguín, 2008Olguín HJ. Extemporaneous suspension of Propafenone: Attending lack of pediatric formulations in Mexico. Pediatr Cardiol. 2008;29(5):1077-81.
|
Propranolol |
120 days at 25 ºC and 4 ºC |
Ensom et al., 2013Ensom MHH, Kendrick J, Rudolph S, Decarie D. Stability of propranolol in extemporaneously compounded suspensions. Can J Hosp Pharm. 2013;66(2):118-24.
|
Pyridoxine |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Quinapril |
6 weeks at 5 ºC |
Freed et al., 2005Freed AL, Silbering SB, Kolodsick KJ, Rossi DT, Mahjour M, Kingsmill CA. The development and stability assessment of extemporaneous pediatric formulations of Accupril. Int J Pharm. 2005;304(1-2):135-144.
|
Ribavirin |
28 days at 4 ºC |
Chan, Tong, Chow, 2004Chan JP, Tong HHY, Chow AHL. Stability of extemporaneous oral Ribavirin liquid preparation. Int J Pharml Compounding. 2004;8(6):486-488.
|
Saquinavir |
20 days at 5 ºC or 25 ºC |
Tan, Thenmozhiyal, Ho, 2003Tan LK, Thenmozhiyal JC, Ho PC. Stability of extemporaneously prepared saquinavir formulations. J Clin Pharm Ther. 2003;28(6):457-463.
|
Sildenafil |
91 days at 4 ºC or 25 ºC |
Nahata, Morosco, Brady, 2006Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm. 2006;63(3):254-257.
|
Sotalol |
180 days at 5 ºC or 25 ºC in absence of light |
Klovrzová et al., 2016Klovrzová S, Zahálka L, Kříž T, Zahálková O, Matysová L, Šklubalová Z, et al. Extemporaneous sotalol hydrochloride oral solutions for use in paediatric cardiology: formulation and stability study. Eur J HospPharm. 2016;23(1):33-37.
|
Sulfadiazine |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Sulfasalazine |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Tacrolimus |
90 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Terbinafine |
90 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Tetracycline |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Tiagabine |
70 days at 25 ºC |
Nahata, Morosco, 2003Nahata MC, Morosco RS. Stability of tiagabine in two oral liquid vehicles. Am J Health-Syst Pharm. 2003;60(1):75-77.
|
Topiramate |
90 days at 2-8 ºC |
Allen, 2017Allen LV. Topiramate 20 mg/mL oral suspension. US Pharm. 2017;42(5):46-7.
|
Trimethoprim |
90 days at 2-8 ºC at 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|
Vancomycin |
91 days at 4 ºC or 25 ºC |
Smith et al., 2017Smith AD, Rempel G, Szeitz A, Klassen TL, Ensom MHH. Vancomycin 50 mg/mL Suspension in Oral Syrup: Stability in Plastic Bottles and Syringes at 2 Temperatures. Can J Hospital Pharm. 2017;70(3):247-9.
|
Valsartan |
90 days at 2-8 ºC or 22-25 ºC |
Polonini et al., 2016bPolonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016b;71(4):185-191.
|
Warfarin |
30 days at 25 ºC and 45 days at 4 ºC |
Schlatter, Cisternino, 2017Schlatter J, Cisternino S. Stability of warfarin sodium flavoured preservative free oral liquid formulations. Eur J Hosp Pharm. 2017;1-4.
|
Zonisamide |
90 days at 2-8 ºC or 20-25 ºC |
Ferreira et al., 2016Ferreira AO, Polonini AC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J PharmBiomed Anal. 2016;118:105-112.
|